OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
PGNY
Progyny, Inc.
PGNY has the edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PGNY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
PGNY's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over PGNY in the historical PE scenario, which offers more potential upside but is not a forecast.
PGNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 24x | $36.58 | — |
| Cheap | 32x | $34.56 | -5.5% |
| Current | 34x | $36.58 | — |
| Fair | 43x | $46.46 | +27% |
| Expensive | 91x | $98.79 | +170% |
Historical ranges are pointers, not guarantees.
PGNY's PE is in its cheap range at 34x. If earnings grow as analysts expect, today's price would be 24x next year's earnings.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PGNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for PGNY, with profitability improving.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
PGNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.54 | +41% |
| Q3 2026 | $1.09 | +73% |
| Q2 2026 | $0.92 | +56% |
| Q1 2026 | $0.77 | +35% |
| Q4 2025 | $0.65 | +14% |
| Q3 2025 | $0.63 | +8.6% |
| Q2 2025 | $0.59 | -6.3% |
| Q1 2023 | $0.43 | -23% |
| Q4 2022 | $0.30 | -55% |
PGNY has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PGNY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PGNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $341.3M | +8.9% |
| Q2 2026 | $350.5M | +5.3% |
| Q1 2026 | $328.5M | +1.4% |
| Q4 2025 | $318.4M | +6.7% |
| Q3 2025 | $313.3M | +9.3% |
| Q2 2025 | $332.9M | +9.5% |
| Q1 2025 | $324M | +17% |
| Q4 2024 | $298.4M | +11% |
PGNY's revenue has grown year over year every quarter since late 2020: $341M last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +3.4 points |
| Q2 2026 | 11% | +4.1 points |
| Q1 2026 | 11% | +3.3 points |
| Q4 2025 | 4.8% | -0.5 points |
| Q3 2025 | 6.9% | +2.5 points |
| Q2 2025 | 7.3% | +0.5 points |
| Q1 2025 | 7.5% | +0.8 points |
| Q4 2024 | 5.3% | +0.2 points |
PGNY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PGNY on cash flow, with more consistent year-over-year improvement.
PGNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.2M | +2.7% |
| Q2 2026 | $44.2M | -12% |
| Q1 2026 | $39.6M | -16% |
| Q4 2025 | $48.6M | -3.3% |
| Q3 2025 | $46M | +7.6% |
| Q2 2025 | $50.2M | -10% |
| Q1 2025 | $47M | +89% |
| Q4 2024 | $50.3M | +36% |
PGNY generated $180M in free cash flow over the past year, down 7.1% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PGNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -969K shares |
| 1 year | -10% | -9.1M shares |
| 3 years | -20% | -19.7M shares |
| 5 years | -19% | -19.2M shares |
| Available history | +26% | +17M shares |
PGNY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $82.8M |
| Q2 2026 | $30M |
| Q1 2026 | $118.6M |
| Q4 2025 | $81.7M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $55.1M |
PGNY spent $313M buying back its own shares over the past year, about six times what it spent the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over PGNY on leverage, with a lower net debt burden relative to earnings.
PGNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -1.3x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.5x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -1.4x | Net Cash |
| Q4 2024 | -2.3x | Net Cash |
PGNY has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PGNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.2 | Overbought |
| Stochastic | 84.8 | Overbought |
PGNY's weekly RSI is 73 (overbought) and its Stochastic is 85 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over PGNY on valuation relative to its sector.
PGNY PE vs Healthcare Sector
| Metric | PGNY | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 30% above |
| PE % | 21 | 29 | 8 pts below |
PGNY is trading at 34x earnings, a 30% premium to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
PGNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.4 | 25% above |
| 20 week MA | $28.8 | 27% above |
| 50 week MA | $25.0 | 46% above |
| 100 week MA | $23.3 | 57% above |
| 200 week MA | $27.3 | 34% above |
PGNY has climbed back above all five of its weekly moving averages, and it's now 34% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PGNY on returns for 2026, with the stronger performance.
PGNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.0 | $42.2 | +51% |
| 2021 | $42.2 | $51.5 | +22% |
| 2022 | $51.5 | $30.8 | -40% |
| 2023 | $30.8 | $37.2 | +21% |
| 2024 | $37.2 | $16.9 | -55% |
| 2025 | $16.9 | $25.8 | +53% |
| 2026 YTD | $25.8 | $36.6 | +42% |
PGNY has finished higher in four of the last six years, two of them by more than 50%. It's up 42% so far in 2026.